1 September 2015 in Urologic Oncology: Seminars and Original Investigations
10 February 2015 in Prostate Cancer and Prostatic Diseases
TPThe Niddk Urologic Diseases In America Project
The Niddk Urologic Diseases In America Project
+1
Background: Several treatment options for clinically localized prostate cancer currently exist under the established guidelines. We aim to assess nationally representative trends in treatment over time and determine potential geographic variation using two large national claims registries. Methods: Men with prostate cancer insured by Medicare (1998–2006) or a private insurer (Ingenix database, 2002–2006) were identified using International Classification of Diseases-9 and Current Procedural Terminology-4 codes. Geographic variation and trends in the type of treatment utilized over time were assessed. Geographic data were mapped using the GeoCommons online mapping platform. Predictors of any treatment were determined using a hierarchical generalized linear mixed model using the logit link function. Results: The use of radical prostatectomy increased, 33–48%, in the privately insured i3 database while remaining stable at 12% in the Medicare population. There was a rapid uptake in the use of newer technologies over time in both the Medicare and i3 cohorts. The use of laparoscopic-assisted prostatectomy increased from 1% in 2002 to 41% in 2006 in i3 patients, whereas the incidence increased from 3% in 2002 to 35% in 2006 for Medicare patients. The use of neoadjuvant/adjuvant androgen deprivation therapy was lower in the i3 cohort and has decreased over time in both i3 and Medicare. Physician density had an impact on the type of primary treatment received in the New England region; however, this trend was not seen in the western or southern regions of the United States. Conclusions: Using two large national claims registries, we have demonstrated trends over time and substantial geographic variation in the type of primary treatment used for localized prostate cancer. Specifically, there has been a large increase in the use of newer technologies (that is, laparoscopic-assisted prostatectomy and intensity-modulated radiation therapy). These results elucidate the need for improved data collection on prostate cancer treatment outcomes to reduce unwarranted variation in care.
1 August 2019 in Urologic Clinics of North America
15 September 2015 in Cancer
BACKGROUND: Characterizing the role of postchemotherapy retroperitoneal lymph node dissection (PC‐RPLND) after high‐dose chemotherapy (HDCT) has been limited by small sample sizes. This study reports on survival after HDCT with stem cell support and PC‐RPLND as well as histologic findings in the retroperitoneum.METHODS: The prospectively maintained testicular cancer database of Indiana University was queried for patients receiving HDCT with stem cell transplantation before PC‐RPLND. The cause and date of death were obtained through patient chart review and contact with referring physicians. The Kaplan‐Meier method was used to evaluate overall survival (OS). The log‐rank test was used for tests of significance. A multivariate, backward, stepwise Cox regression model was built to evaluate predictors of overall mortality.RESULTS: A total of 92 patients were included in the study. In the entire cohort, the retroperitoneal (RP) histology findings at the time of PC‐RPLND were necrosis (26%), teratoma (34%), and cancer (38%). Sixty‐six patients (72%) harbored either a teratoma or active cancer in the RP specimen at PC‐RPLND. The median follow‐up for the entire cohort was 80.6 months. A total of 28 patients (30%) died during follow‐up. The 5‐year OS rate of the entire cohort was 70%. The most significant predictor of death was PC‐RPLND performed in the desperation setting with elevated markers.CONCLUSIONS: Despite these patients being heavily pretreated with multiple cycles of chemotherapy, including HDCT, approximately three‐fourths were found to have a teratoma and/or active cancer in the retroperitoneum. This underscores the importance of PC‐RPLND for rendering patients free of disease and providing a potential for cure. Cancer 2015;121:4369–75. © 2015 American Cancer Society.
1 April 2018 in Clinical Genitourinary Cancer